肿瘤药学2018，Vol.8Issue(2)：231-235,5.DOI:10.3969/j.issn.2095-1264.2018.02.24
生物标志物联合CD133+细胞数量对良恶性胸腔积液鉴别诊断与治疗效果评估的临床研究
The Value of Biomarker Combined with CD133+Cell Counter Detection in the Differential Diagnosis and Clinical Effect Evaluation of Benign and Malignant Pleural Effusion
摘要
Abstract
Objective To explore the value of adenosine deaminase (ADA), C-reactive protein (CRP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA125), CD133+and phage phage amplification of mycobacterium tuberculosis (TB-PhaB) detection in the differ-ential diagnosis and clinical effect evaluation of tuberculous pleural effusion and lung cancer with pleural effusion. Methods 40 patients with pleural effusion were enrolled in this study, and divided into tuberculous pleural effusion group (n=18) and lung cancer with pleural effusion group (n=22). The detection of ADA, CRP, TB-PhaB, CEA, CA125 were carried out and the relationship between the CD133+cell and clinical efficacy was explored. Results The levels of ADA, CRP, CEA and CA125 in patients with tuberculous pleural effusion were respectively (42.93±15.95) U·L-1, (32.61±8.73) mg·L-1,(1.61±0.52) ng·mL-1, (532.61±195.46) U·mL-1, while those of lung cancer pa-tients with pleural effusion were respectively (16.95±8.76) U·L-1, (12.57±7.03) mg·L-1, (246.29±115.82) ng·mL-1and (1032.79±315.27) U·mL-1. All were significantly different between the two groups (P<0.05). The positive rate of TB-PhaB in patients with tuberculous pleu-ral effusion was 55.6%. No positive TB-PhaB was found in lung cancer patients with pleural effusion. The area under ROC curves of CRP, ADA, CA125, CEA were respectively 0.919, 0.905, 0.957, 0.882. The sensitivity of CRP, ADA, CA125, CEA were respectively 94.9%, 76.1%, 90.2%, 91.9%, and specificity were respectively 91.3%, 94.3%, 71.3%, 94.7%. After treatment, there were 8 cases of PR, 9 cases of SD, 5 cases of PD, and no cases of CR in lung cancer patients with pleural effusion. The median numbers of CD133+cells in the PR, SD, PD patients were respectively 2 (0~31), 35 (0~317), 285 (15~1097) /10 mL, and the difference was significant (x2=7.317, P<0.05). Conclu-sion The detection of ADA, CRP, CEA, CA125, CD133+cells and TB-PhaB can differentiate the benign and malignant pleural effusion and predict the clinical efficacy of treatment on lung cancer patients with pleural effusion.关键词
良恶性胸腔积液/生物标志物/TB-PhaB/CD133+细胞Key words
Benign and malignant pleural effusion/Biomarker/TB-PhaB/CD133+cells分类
医药卫生引用本文复制引用
王进,胡忠,甘易玲,郑娟,王洋,刘汝建..生物标志物联合CD133+细胞数量对良恶性胸腔积液鉴别诊断与治疗效果评估的临床研究[J].肿瘤药学,2018,8(2):231-235,5.基金项目
2015年重庆市卫生计生委医学科研项目(2015XMSB0001140). （2015XMSB0001140）
